An autoimmune disease is when the body’s immune system attacks its cells and organs. This article discusses the autoimmune diseases that resulted from COVID-19 and the COVID jabs.
After reading, you will know that the autoimmune diseases after COVID-19 and its jabs are similar.
That is not surprising because the spike protein encoded in the mRNA jabs (Pfizer, Moderna) and vector vaccines (AstraZeneca, Janssen) came from the most dangerous part of the SARS-CoV-2, the spike protein.
The spike proteins have the same effect in COVID-19 and the jabs
You will also notice that there is no mention of myocarditis after COVID-19, even though it includes young men. However, myocarditis is the second most common autoimmune disease after the shots.
Note: Big pharma and the corrupt mass media sold COVID-19 shots to people by saying that the myocarditis risk is higher in COVID-19 than with COVID injections.
Two research papers are discussed here. Incident autoimmune diseases associated with a SARS-CoV-2 infection[1] and Autoimmune and autoinflammatory conditions after COVID-19 vaccination.[2]
If you want to know more about all the conditions, click on them. They have embedded links.
Autoimmune diseases after COVID-19
The first paper is a new preprint from Germany, and the subjects were local. It includes people who had COVID-19 in 2020 before the COVID shots were released. All are not vaccinated. The authors followed from three to fifteen months to see if they would develop autoimmune diseases.
Six hundred forty-one thousand four hundred seven individuals with COVID-19 were compared to a control group of 1,907,992 who did not have COVID.
Both groups were matched.
The most common autoimmune conditions after COVID-19
- Wegener’s disease
- Behcet’s disease
- Sarcoidosis
- Arteritis Temporalis
- Hashimoto thyroiditis
- Graves’ disease
- Psoriasis
- Rheumatoid arthritis
- Sjögren syndrome
- Guillain-Barré syndrome
Notably, the first three conditions above are rare.
The Incidence Rate Ratio (IRR) below compares the incidence rate between the COVID and non-COVID groups. IR COVID-19/IR weighted controls calculate IRR.
Autoimmune diseases after COVID Shots
The second study, Autoimmune and autoinflammatory conditions after COVID-19 vaccination.[2] is a compilation of case reports published in the Journal of Immunology.
The authors are from Colombia’s Center for Autoimmune Diseases Research (CREA) and the University of California in Davis in the US.
It includes 934 cases from published reports globally. Here is what they found:
- Most patients (53.6%) were women, with a median age of 48.
- The onset of autoimmune disease is fast. The median period between immunization and the start of symptoms was eight days (IQR: 3 to 14).
- New-onset conditions were observed in 81.5% (n: 756) of the cases.
- New-onset events were seen more in the first doses.
- Relapsing diseases were related to the second dose.
- New-onset conditions and relapsing diseases were more common in women
- No deaths were recorded in relapsed cases, while 4.7% of patients with new-onset conditions died.
4.7% is a lot, and it’s higher than the COVID death rate. A greater risk than benefit.
The most common new-onset autoimmune diseases following vaccination:
- Immune thrombocytopenia (Low platelet count)
- Myocarditis (not mentioned as an issue after COVID-19 in the study above)
- Guillain-Barré syndrome (autoimmune disease affecting the brain and nerves)
The most common relapsed autoimmune diseases.
- Immune thrombocytopenia
- Psoriasis
- IgA nephropathy (kidney disease)
- Systemic lupus erythematosus (multi-system)
Autoimmune diseases after COVID vaccinations
| New onset (n: 756) | Relapsing (n: 172) | P value | |
|---|---|---|---|
| Demographic characteristics | |||
| Age (IQR) | 48 (33–66) | 46 (34–66) | 0.7851 |
| Days of onset of symptoms since vaccination (IQR) | 8 (3–14) | 7 (2–13.25) | 0.0094 |
| Gender | 0.0081 | ||
| Male | 359/740 (48.5%) | 63/170 (37.1%) | |
| Female | 381/740 (51.5%) | 107/170 (62.9%) | |
| Systemic lupus erythematosus | 15 (2.0%) | 11 (6.4%) | 0.0038 |
| Antiphospholipid syndrome | 4 (0.5%) | 0 (0.0%) | 1.0000 |
| Immune thrombocytopenia | 221 (29.2%) | 33 (19.2%) | 0.0079 |
| Disseminated intravascular coagulation | 3 (0.4%) | 0 (0.0%) | 1.0000 |
| Thrombotic microangiopathy | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Autoimmune acquired factor XIII/13 | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Autoimmune hemolytic anemia | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Acute disseminated encephalomyelitis | 5 (0.7%) | 1 (0.6%) | 1.0000 |
| Encephalitis | 6 (0.8%) | 0 (0.0%) | 0.5998 |
| Guillain-Barré syndrome | 73 (9.7%) | 1 (0.6%) | < 1e-04 |
| Chronic ínflammatory demyelinating polyneuropathy | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Multiple sclerosis | 9 (1.2%) | 1 (0.6%) | 0.6984 |
| Transverse myelitis | 17 (2.2%) | 0 (0.0%) | 0.0541 |
| Optic perineuritis | 3 (0.4%) | 0 (0.0%) | 1.0000 |
| Neuromyelitis Optica | 5 (0.7%) | 0 (0.0%) | 0.5907 |
| Inflammatory peripheral neuropathies | 3 (0.4%) | 0 (0.0%) | 1.0000 |
| Myasthenia Gravis | 4 (0.5%) | 2 (1.2%) | 0.3086 |
| Uveitis | 16 (2.1%) | 8 (4.7%) | 0.0658 |
| Graves’ disease | 42 (5.6%) | 8 (4.7%) | 0.8513 |
| Hashimoto thyroiditis | 42 (5.6%) | 6 (3.5%) | 0.3415 |
| Type 1 diabetes mellitus | 5 (0.7%) | 0 (0.0%) | 0.5907 |
| Primary adrenal insufficiency | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Autoimmune hepatitis | 24 (3.2%) | 1 (0.6%) | 0.0662 |
| Pancreatitis | 4 (0.5%) | 0 (0.0%) | 1.0000 |
| Acute granulomatous nephritis | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Acute interstitial nephritis | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| ANCA associated glomerulonephritis | 5 (0.7%) | 0 (0.0%) | 0.5907 |
| Anti-GBM nephritis | 3 (0.4%) | 1 (0.6%) | 0.5602 |
| Minimal change disease | 24 (3.2%) | 9 (5.2%) | 0.1781 |
| IgG4 related nephritis | 1 (0.1%) | 1 (0.6%) | 0.3365 |
| Membranous nephropathy | 4 (0.5%) | 1 (0.6%) | 1.0000 |
| Crescentic glomerulonephritis | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| IgA nephropathy | 22 (2.9%) | 16 (9.3%) | 0.0008 |
| Focal segmental glomerulosclerosis | 1 (0.1%) | 1 (0.6%) | 0.3365 |
| Glomerulonephritis phospholipase A2 receptor | 1 (0.1%) | 2 (1.2%) | 0.0900 |
| Paroxysmal nocturnal hemoglobinuria | 1 (0.1%) | 1 (0.6%) | 0.3365 |
| Myocarditis | 71 (9.4%) | 1 (0.6%) | < 1e-04 |
| Pericarditis | 7 (0.9%) | 2 (1.2%) | 0.6758 |
| Sjogren′s syndrome | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Rheumatoid arthritis | 3 (0.4%) | 6 (3.5%) | 0.0019 |
| Arthritis | 12 (1.6%) | 2 (1.2%) | 1.0000 |
| Polymyalgia Rheumatica | 13 (1.7%) | 4 (2.3%) | 0.5361 |
| Myositis | 5 (0.7%) | 0 (0.0%) | 0.5907 |
| Gout | 1 (0.1%) | 1 (0.6%) | 0.3365 |
| Adult-onset Still Disease | 12 (1.6%) | 5 (2.9%) | 0.2218 |
| Behcet disease | 1 (0.1%) | 5 (2.9%) | 0.0011 |
| ANCA vasculitis | 3 (0.4%) | 4 (2.3%) | 0.0251 |
| Granulomatosis with polyangiitis | 1 (0.1%) | 0 (0.0%) | 1.0000 |
| Raynaud phenomenon | 1 (0.1%) | 0 (0.0%) | 1.0000 |
| Giant cell arteritis | 3 (0.4%) | 0 (0.0%) | 1.0000 |
| Henoch-Schönlein purpura | 10 (1.3%) | 1 (0.6%) | 0.6996 |
| Leukocytoclastic vasculitis | 16 (2.1%) | 1 (0.6%) | 0.3389 |
| Urticarial vasculitis | 3 (0.4%) | 0 (0.0%) | 1.0000 |
| Microscopic polyangiitis | 1 (0.1%) | 3 (1.7%) | 0.0217 |
| Eosinophilic granulomatosis with polyangiitis | 2 (0.3%) | 1 (0.6%) | 0.4597 |
| Polyarteritis nodosa | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Immune complex vasculitis | 1 (0.1%) | 1 (0.6%) | 0.3365 |
| Kawasaki Disease | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Temporal arteritis-like disease | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Löfgren syndrome | 3 (0.4%) | 0 (0.0%) | 1.0000 |
| Erythema nodosum | 3 (0.4%) | 1 (0.6%) | 0.5602 |
| Neurosacroidosis | 1 (0.1%) | 1 (0.6%) | 0.3365 |
| Macrophage activation syndrome | 1 (0.1%) | 0 (0.0%) | 1.0000 |
| Hypereosinophilic syndrome | 1 (0.1%) | 1 (0.6%) | 0.3365 |
| Hemophagocytic lymphohistiocytosis | 7 (0.9%) | 0 (0.0%) | 0.3599 |
| Fever of unknown origin | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Multisystem inflammatory syndrome | 7 (0.9%) | 0 (0.0%) | 0.3599 |
| Systemic sclerosis | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Vitiligo | 3 (0.4%) | 0 (0.0%) | 1.0000 |
| Dermatomyositis | 5 (0.7%) | 1 (0.6%) | 1.0000 |
| Psoriasis | 3 (0.4%) | 22 (12.8%) | < 1e-04 |
| Bullous pemphigoid | 23 (3.0%) | 4 (2.3%) | 0.8029 |
| Pemphigus vulgaris | 7 (0.9%) | 1 (0.6%) | 1.0000 |
| Pemphigus foliaceus | 1 (0.1%) | 0 (0.0%) | 1.0000 |
| Acute dyshidrotic eczema | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Stevens-Johnson syndrome | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Linear IgA bullous dermatosis | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Chilblain like lesions | 3 (0.4%) | 0 (0.0%) | 1.0000 |
| Sweet syndrome | 4 (0.5%) | 0 (0.0%) | 1.0000 |
| Lichen planus | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Pigmented purpuric dermatosis | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Exanthematous pustulosis | 2 (0.3%) | 0 (0.0%) | 1.0000 |
| Sarcoidosis | 2 (0.3%) | 0 (0.0%) | 1.0000 |
I wrote articles about some of these case reports.
- Polymyalgia Rheumatica: an adverse effect of the COVID jabs
- Sky High Blood Sugars After the COVID Shots
- Myocarditis in the Autopsies of Five that “Suddenly Died”
- Giant Cell Arteritis after COVID-19 and its shots
- Children with Post Vaccine Myocarditis have Spike Proteins in their Blood
The figure below shows the vaccines associated with the autoimmune conditions
If you know anyone who had adverse events after the COVID shots, do yourself and the coming generations a favor. Report to VAERS.
The Complete List of the Pfizer Adverse Events of Special Interest
A personal note:
My former employer told me to get the COVID shots. I did some homework to learn more. The result of my research resulted in the following articles.
- COVID-19, Autoimmunity and Vaccination, Part 1
- COVID-19, Autoimmunity, and Vaccination Part 2
- COVID-19, Autoimmunity, and Vaccination Part 3
- Molecular Mimicry between the SARS-CoV-2 and the Breathing Center
- Molecular mimicry between the spike protein and humans can shut down platelet production
- The SARS-CoV-2 spike protein cross-reacts with eleven human proteins to cause autoimmune diseases
I quit my job. (No jab, no work) And never regretted it. After a year, the authors who warned about autoimmunity and the COVID shots were proven right.
- Diseases From SARS-CoV-2 Autoantibodies
- Autoimmune antibodies and diseases after COVID-19 disease and injections
The spike protein might be inside your system if you had the shots. If you have never had the jab but have Long COVID syndrome, there may be a solution.
- Bromelain and Acetylcysteine Combined Destroy the SARS-CoV-2 spike protein
- Nattokinase Degrades the SARS-CoV-2 Spike Protein
- Another Study shows Nattokinase can Destroy the S1 Spike Protein
Truth heals. Lies kill. Don’t Get Sick!
Knowledge about Covid-19 is rapidly evolving. Stay current by subscribing. Feel free to share and like.
Follow me on Gettr, Truth Social, Gab, Parler, Twitter, Facebook, Follow, and Telegram.
If you find value in this website, please consider buying a coffee to show your support.
References:
- Tesch et al. Incident autoimmune diseases in association with a SARS-CoV-2 infection: A matched cohort study.
- Rodríguez Y et al. Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun. 2022 Oct;132:102898. doi: 10.1016/j.jaut.2022.102898. Epub 2022 Aug 24. PMID: 36041291; PMCID: PMC9399140.
© 2018 – 2023 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases.